Evidence map›Paper›PMID 30721319›Full record

ReviewCellular and molecular life sciences : CMLS2019

Therapeutic potential of menstrual blood-derived endometrial stem cells in cardiac diseases.

Yanli Liu, Rongcheng Niu, Wenzhong Li, Juntang Lin, Christof Stamm, Gustav Steinhoff, Nan Ma

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Repairing and Regenerating Injured Endometrium Methods.Reproductive sciences (Thousand Oaks, Calif.) · 2023
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Yanli LiuStem Cell and Biotherapy Technology Research Center, College of Life Science and Technology, Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, 453003, People's Republic of China.ORCID http://orcid.org/0000-0003-0886-8907
Rongcheng NiuStem Cell and Biotherapy Technology Research Center, College of Life Science and Technology, Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, 453003, People's Republic of China.
Wenzhong LiInstitute of Chemistry and Biochemistry, Free University Berlin, 14195, Berlin, Germany. fuli@zedat.fu-berlin.de.
Juntang LinStem Cell and Biotherapy Technology Research Center, College of Life Science and Technology, Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, 453003, People's Republic of China. linjtlin@126.com.
Christof StammDeutsches Herzzentrum Berlin (DHZB), Berlin, Germany.
Gustav SteinhoffDepartment of Cardiac Surgery, Reference and Translation Center for Cardiac Stem Cell Therapy, University Rostock, 18055, Rostock, Germany.
Nan MaInstitute of Chemistry and Biochemistry, Free University Berlin, 14195, Berlin, Germany.
Freie Universität Berlin · DEXinxiang Medical University · CNHelmholtz-Zentrum Hereon · DEHumboldt-Universität zu Berlin · DEUniversity of Rostock · DE

Funding

National Natural Science Foundation of China 81671619National Natural Science Foundation of China 81771226Xinxiang Foundation 20172DCG-03Xinxiang Foundation ZD17008
6 · The paper itself

Abstract

Despite significant developments in medical and surgical strategies, cardiac diseases remain the leading causes of morbidity and mortality worldwide. Numerous studies involving preclinical and clinical trials have confirmed that stem cell transplantation can help improve cardiac function and regenerate damaged cardiac tissue, and stem cells isolated from bone marrow, heart tissue, adipose tissue and umbilical cord are the primary candidates for transplantation. During the past decade, menstrual blood-derived endometrial stem cells (MenSCs) have gradually become a promising alternative for stem cell-based therapy due to their comprehensive advantages, which include their ability to be periodically and non-invasively collected, their abundant source material, their ability to be regularly donated, their superior proliferative capacity and their ability to be used for autologous transplantation. MenSCs have shown positive therapeutic potential for the treatment of various diseases. Therefore, aside from a brief introduction of the biological characteristics of MenSCs, this review focuses on the progress being made in evaluating the functional improvement of damaged cardiac tissue after MenSC transplantation through preclinical and clinical studies. Based on published reports, we conclude that the paracrine effect, transdifferentiation and immunomodulation by MenSC promote both regeneration of damaged myocardium and improvement of cardiac function.

Indexed as

Stem Cell TransplantationAdultAgedCardiac RehabilitationCardiovascular DiseasesCell- and Tissue-Based TherapyCell TransdifferentiationEndometriumFemaleHumansMenstruationStem CellsYoung AdultCardiac diseaseCardiac regenerationMenstrual blood-derived endometrial stem cellsStem cell-based therapy

Identifiers

PMID30721319
PMCPMC11105669
OpenAlexW2912387636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.